Individual genetic association studies examining the relationship between the MMP-9 -1562C/T polymorphism (rs3918242) and preeclampsia risk have yielded inconsistent results.
Objective: This study aims to evaluate the association between the MMP-9 -1562C/T polymorphism and preeclampsia risk using meta-analysis.
Materials and methods: Relevant studies were identified by searching PubMed database. Data were extracted and statistical analysis was performed using STATA 12.0 software. A total of six publications involving 871 cases and 845 controls were included in this meta-analysis.
Results: Combined analysis revealed no association between the MMP-9 -1562C/T polymorphism and preeclampsia risk (allelic model: OR = 1.10, 95% CI 0.86-1.41, Pheterogeneity = 0.07; recessive model: OR = 0.38, 95% CI 0.14-1.01, Pheterogeneity = 0.64; dominant model: OR = 1.09, 95% CI 0.70-1.69, Pheterogeneity = 0.01; homozygous model: OR = 0.41, 95% CI 0.15-1.09, Pheterogeneity = 0.67; heterozygous model: OR = 1.36, 95% CI 0.80-2.29, Pheterogeneity = 0.01). Similarly, subgroup analysis by ethnicity showed that MMP-9 -1562C/T polymorphism was not associated with preeclampsia risk in Brazilian (allelic model: OR = 1.37, 95% CI 0.92-2.05, Pheterogeneity = 0.61; recessive model: OR = 0.80, 95% CI 0.18-3.57, Pheterogeneity = 0.58; dominant model: OR = 1.12, 95% CI 0.60-2.10, Pheterogeneity = 0.03; homozygous model: OR 0.87, 95% CI 0.19-3.94, Pheterogeneity = 0.62; heterozygous model: OR = 1.55, 95% CI 0.99-1.75, Pheterogeneity = 0.32).
Conclusion: This meta-analysis indicated that MMP-9 -1562C/T polymorphism was not associated with preeclampsia risk. However, large well-designed, multi-center epidemiological studies should be carried out in these and other ethnic populations to confirm our findings.